• Eur J Gastroenterol Hepatol · Jun 2021

    Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B.

    • Hye Yeon Chon, Yeon Seok Seo, Jung Il Lee, Byung Seok Kim, Byoung Kuk Jang, Sang Gyune Kim, Ki Tae Suk, In Hee Kim, Jin-Woo Lee, Young Eun Chon, Moon Young Kim, Soung Won Jeong, Han Ah Lee, Sun Young Yim, Soon Ho Um, LeeHyun WoongHWDepartment of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine., Kwan Sik Lee, Jeong Eun Song, Chang Hyeong Lee, Woo Jin Chung, Jae Seok Hwang, Jeong-Ju Yoo, Young Seok Kim, Dong Joon Kim, Chang Hun Lee, Jung Hwan Yu, Yeon Jung Ha, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Seong Hee Kang, Soon Koo Baik, Jae Young Jang, Sang Jun Suh, Young Kul Jung, Beom Kyung Kim, Jun Yong Park, KimDo YoungDYDepartment of Internal Medicine, Yonsei University College of Medicine., Sang Hoon Ahn, Kwang-Hyub Han, Hyung Joon Yim, Seung Up Kim, and Korean Transient Elastography Study Group.
    • Department of Internal Medicine, Yonsei University College of Medicine.
    • Eur J Gastroenterol Hepatol. 2021 Jun 1; 33 (6): 885-893.

    ObjectiveThe liver stiffness-based risk prediction models predict hepatocellular carcinoma (HCC) development. We investigated the influence of antiviral therapy (AVT) on liver stiffness-based risk prediction model in patients with chronic hepatitis B (CHB).MethodsPatients with CHB who initiated AVT were retrospectively recruited from 13 referral Korean institutes. The modified risk estimation for hepatocellular carcinoma in chronic hepatitis B (mREACH-B) model was selected for the analysis.ResultsBetween 2007 and 2015, 1034 patients with CHB were recruited. The mean age of the study population (639 men and 395 women) was 46.8 years. During AVT, the mREACH-B score significantly decreased from the baseline to 3 years of AVT (mean 9.21 → 7.46, P < 0.05) and was maintained until 5 years of AVT (mean 7.23, P > 0.05). The proportion of high-risk patients (mREACH-B score ≥11) was significantly reduced from the baseline to 2 years of AVT (36.4% → 16.4%, P < 0.001) and was maintained until 5 years of AVT (12.2%, P > 0.05). The mREACH-B scores at baseline and 1 year of AVT independently predicted HCC development (hazard ratio = 1.209-1.224) (all P < 0.05). The cumulative incidence rate of HCC was significantly different at 5 years of AVT among risk groups (high vs. high-intermediate vs. low-intermediate vs. low) from baseline (4.5% vs. 3.2% vs. 1.5% vs. 0.8%) and 1 year (11.8% vs. 4.6% vs. 1.8% vs. 0.6%) (all P < 0.05, log-rank tests).ConclusionsThe mREACH-B score was dynamically changed during AVT. Thus, repeated assessment of the mREACH-B score is required to predict the changing risk of HCC development in patients with CHB undergoing AVT.Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…